Manufacturer
CCM Duopharma BioTech
Contents
Perindopril erbumine
Indication
Hypertension & symptomatic heart failure. Stable coronary artery disease: Risk reduction of cardiac events in patients with a history of MI &/or revascularisation.
Instruction
Should be taken on an empty stomach: Take before meals.
Drug interaction
Increased hypokalaemia occurrence w/ aliskiren, K salts or K-sparing diuretics (eg, triamterene, amiloride, eplerenone, spironolactone), ACE inhibitors, angiotensin II receptor antagonists, NSAIDs, heparins, ciclosporin or tacrolimus, trimethoprim. Increased risk of angioneurotic oedema w/ estramustine, gliptines. Reversible increase in serum conc & toxicity of lithium. Increased blood-glucose lowering effect w/ antidiabetic agents (eg, insulins, oral hypoglycaemic agents). Increased antihypertensive effect w/ baclofen. Increased risk of worsening renal function w/ NSAIDs. Increased hypotensive effect w/ concomitant antihypertensives, vasodilators, nitroglycerin & other nitrates, TCAs, antipsychotics, anaesth. Reduced antihypertensive effect by sympathomimetics. Nitritoid reactions w/ injectable gold (Na aurothiomalate).
Malaysia
